Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (51-60 of 413) with videos related to

Pageof 42
Sort By:
Cancer|December 22, 2007
Prohibition against competing cancer clinical trials: a counter argumentMaurie Markman
Oncology|December 22, 2007
A need to document a role for palliative chemotherapy in the management of progressive malignant diseaseMaurie Markman
Oncology|November 7, 2012
Optimizing the use of oral anti-neoplastic drug therapyMaurie Markman
Current Pharmaceutical Design|September 29, 2012
Risk of cervical cancer after HPV vaccinationMaurie Markman
F1000 Medicine Reports|October 16, 2010
Update on the utility of prognostic biomarkers in ovarian cancerMaurie Markman
Oncology (Williston Park, N.Y.)|March 17, 2017
Maurie Markman on the Groundbreaking TAPUR TrialMaurie Markman
Oncology|August 8, 2019
Lenvatinib Real-Life ExperienceMaurie Markman
The Oncologist|February 3, 2004
Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research communityMaurie Markman
Cleveland Clinic Journal of Medicine|January 27, 2004
Genetic discrimination arising from cancer risk assessments: a societal dilemmaMaurie Markman
Current Oncology Reports|May 27, 2004
Translating the results of phase III randomized cancer trials into the language of physician obligation to patientsMaurie Markman
Pageof 42

Showing results (51-60 of 413) with videos related to

Sort By:
Pageof 42
Cancer|December 22, 2007
Prohibition against competing cancer clinical trials: a counter argumentMaurie Markman
Oncology|December 22, 2007
A need to document a role for palliative chemotherapy in the management of progressive malignant diseaseMaurie Markman
Oncology|November 7, 2012
Optimizing the use of oral anti-neoplastic drug therapyMaurie Markman
Current Pharmaceutical Design|September 29, 2012
Risk of cervical cancer after HPV vaccinationMaurie Markman
F1000 Medicine Reports|October 16, 2010
Update on the utility of prognostic biomarkers in ovarian cancerMaurie Markman
Oncology (Williston Park, N.Y.)|March 17, 2017
Maurie Markman on the Groundbreaking TAPUR TrialMaurie Markman
Oncology|August 8, 2019
Lenvatinib Real-Life ExperienceMaurie Markman
The Oncologist|February 3, 2004
Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research communityMaurie Markman
Cleveland Clinic Journal of Medicine|January 27, 2004
Genetic discrimination arising from cancer risk assessments: a societal dilemmaMaurie Markman
Current Oncology Reports|May 27, 2004
Translating the results of phase III randomized cancer trials into the language of physician obligation to patientsMaurie Markman
Pageof 42